AstraZeneca Calquence gets conditional nod in China for adults with previously treated mantle cell lymphoma Ruchika Sharma26 March 2023 10:00 AM ISTMantle cell lymphoma is a rare B-cell malignancy subtype and is typically clinically aggressive with a poor prognosis.
All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab Dr. Divya Colin25 March 2023 6:00 PM ISTNew Delhi: Granting the protocol amendment proposal presented by drug major AstraZeneca for anticancer drug Durvalumab, the Subject Expert Committee...
Conduct Phase III CT : CDSCO panel tells AstraZeneca for anticancer drug Olaparib Film coated Tablet Dr. Divya Colin17 March 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the drug major...
AstraZeneca Gets CDSCO Panel nod to import, market Trastuzumab deruxtecan for breast cancer Dr. Divya Colin16 March 2023 6:00 PM ISTNew Delhi: Granting the local Phase III clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
AstraZeneca Enhertu shows clinically meaningful, durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial Ruchika Sharma8 March 2023 1:00 PM ISTHER2 is a tyrosine kinase receptor protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.
AstraZeneca concludes acquisition of CinCor Pharma Ruchika Sharma26 Feb 2023 2:30 PM ISTUK: AstraZeneca has announced the successful completion of the acquisition of CinCor Pharma, Inc., a US-based clinical-stage biopharmaceutical...
AstraZeneca enters license agreement with KYM Biosciences for CMG901 Ruchika Sharma26 Feb 2023 10:00 AM ISTUK: AstraZeneca and KYM Biosciences Inc. have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody...
AstraZeneca-Daiichi Sankyo Enhertu approved in China for breast cancer Ruchika Sharma25 Feb 2023 1:30 PM ISTUK: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult...
AstraZeneca Calquence tablet formulation approved in EU for adults with chronic lymphocytic leukaemia Ruchika Sharma23 Feb 2023 11:30 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of Bruton's tyrosine kinase (BTK).
AstraZeneca India gets CDSCO nod for Durvalumab to treat biliary tract cancer Ruchika Sharma17 Feb 2023 12:00 PM ISTNew Delhi: Science-led biopharmaceutical company, AstraZeneca India, has announced additional indication approval from Central Drugs...
Natco Pharma announces submission of ANDA with USFDA for generic version of Olaparib Tablets Ruchika Sharma13 Feb 2023 12:25 PM ISTOlaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer.
Covishield even worse in terms of cardiovascular effects, heart attacks and strokes: Eminent British Indian Cardiologist Roshni Dhar8 Feb 2023 4:39 PM ISTEminent British Indian Cardiologist Dr Aseem Malhotra, who has been leading international calls for the suspension of mRNA COVID 19 vaccines, said on...
